8 / 28
2017 American Academy of
Dermatology Annual Meeting
3–7 MARCH 2017 • ORLANDO, FLORIDA, USA
The 2017 AAD Annual Meeting sawmore
than 1100 speakers present new research
and clinical information on the diagnosis
and treatment of skin, hair and nail
conditions. The PracticeUpdate editorial
team and contributors Dr Anna Wile,
Dr Sarah Chamlin and Dr Jeffrey Scott,
present highlights from the meeting.
2017 AADANNUALMEETING
Dr AnnaWile’s take-aways
Dr Wile, a regular contributor to
PracticeUpdate Dermatology
,
offers her key “take-aways”
from the 2017 AAD Annual
Meeting.
S045
– Teledermatology working for you:
customizing use in the changing healthcare
environment.
Teledermatology and the future of medicine –
C Kovarik
•
Teledermatology will very likely be a component of
the future dermatology landscape, and we should
actively participate in its development to ensure a
high-quality execution. Preferred modalities include
live-interactive and store and forward.
•
Teledermatology will be a means to deliver care in
areas of poor dermatology access and in under-
served subspecialties (eg, inpatient dermatology)
to improve outcomes. However, we must be vigi-
lant to detect poor-quality teledermatology, which
could compound our access problems. Unsavoury
teledermatology providers could compromise
potential opportunities.
•
We as dermatologists must advocate for payments
to us as providers to care for our patients instead
of corporate telemedicine dominating the market.
S068
– Therapeutic and diagnostic pearls
What’s new in infectious disease –
T Rosen
•
We could be facing a Zika outbreak this summer in
the US. Although there are no FDA-approved treat-
ments for Zika, a recent screen of FDA-approved
drugs found several that could inhibit Zika infection.
These drugs included mycolic acid (pregnancy
category D), ivermectin (pregnancy category C),
sertraline (pregnancy category C), and daptomycin
(pregnancy category B).
1
Areas predicted to be
affected are the Gulf Coast and lower Atlantic sea-
board. Commercial tests for Zika are now available.
The FDA is debating releasing genetically modified
male
Aedes
mosquitoes into the Florida Keys, which
would yield nonviable larvae. This has been a suc-
cessful tactic in the Cayman Islands and Brazil.
•
New vaccines to be on the lookout for are the
dengue fever vaccine, which is nearly 100% effec-
tive, and the nonavalent HPV vaccine.
•
Syphilis is on the rise and there is a national Bicillin
shortage. Minocycline 100 mg twice daily for 28
days is 87.3% effective and a good alternative.
•
Omadacycline is the first antibiotic in the aminomethyl-
cycline class. It has a broad spectrum that includes
CRE, VRE, MRSA, VRSA, and clindamycin- and erythro-
mycin-resistant strep. It will be available as a single-day
oral or IV dosing. It will be highly resistance resistant.
2
CONFERENCE COVERAGE
8
PRACTICEUPDATE DERMATOLOGY